Abstract
Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Optimal Management of Hypertension in patients with Ischemic Heart Disease
Volume: 7 Issue: 3
Author(s): Debabrata Mukherjee and Charles L. Campbell
Affiliation:
Abstract: Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Export Options
About this article
Cite this article as:
Mukherjee Debabrata and Campbell L. Charles, Optimal Management of Hypertension in patients with Ischemic Heart Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (3) . https://dx.doi.org/10.2174/187152509789105435
DOI https://dx.doi.org/10.2174/187152509789105435 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic Acid as Novel Fibrinogen Receptor Antagonists
Medicinal Chemistry Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry Sudden Unexpected Death in Infancy and the Dilemma of Defining the Sudden Infant Death Syndrome
Current Pediatric Reviews The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry Effects of Statins on Bone Markers, Bone Mineral Density and Fractures. Possible Role in Osteoporosis Treatment
Current Pharmaceutical Analysis Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism A Review on Pharmacological Properties of Coumarins
Mini-Reviews in Medicinal Chemistry Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Detection of Klebsiella Antibodies and HLA-B27 Allelotypes Could be Used in the Early Diagnosis of Ankylosing Spondylitis with a Potential for the Use of “Low Starch Diet” in the Treatment
Current Rheumatology Reviews